GluBio Therapeutics is a San Diego- and Shanghai-based biotech developing novel targeted protein degraders using a proprietary TPD discovery platform. Led by founder and CEO Gang Lu, Ph.D., the company is advancing a diverse pipeline of highly selective small-molecule degraders across oncology and immunology. The company plans to use new funding to advance two molecular glue degraders into the clinic for hematological malignancies and to accelerate lead-optimization entry of three first-in-class TPD programs for solid tumors and inflammatory diseases. GluBio also intends to further upgrade its proprietary TPD discovery platform and screening capabilities tailored for rapid discovery and optimization of small-molecule protein degraders for ‘undruggable’ targets. GluBio closed a $22M Series A+ and has raised nearly $90M in total capital since its establishment in March 2021. The company is dedicated to addressing unmet medical needs with targeted protein degraders enabled by its screening capabilities.

Total raised

$22M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2022